1315 Capital’s Post

"Another webinar conquered! Just wrapped up the 32nd SPSR webinar on 'From Lab to Life: Unveiling chemotherapy-induced neuropathic pain using cutting-edge animal models' organised by Society of Pharmaceutical Sciences and Research  .  It was an exhilarating session, discussing the latest advancements in our field. Kudos to the exceptional speakers and attendees who made this event a success. Looking forward to implementing these insights in our quest to improve patient care. Stay tuned for more groundbreaking webinars on the horizon! Thanks Society of Pharmaceutical Sciences and Research  for organising a helpful knowledgeable webinar. #WebinarConqueror #CuttingEdgeResearch #NeuropathicPain"

🌐 Certificate of Participation in Webinar I am delighted to share that I actively participated in the 32nd webinar organized by #SPSR on the intriguing topic, "From Lab to Life: Unravelling Chemotherapy-Induced Neuropathic Pain with Cutting-Edge Animal Models." 🏆 Certificate Issued By: Society of Pharmaceutical Science and Research. I would like to express my gratitude to the organizers for providing valuable insights into this cutting-edge research area. The knowledge gained during this webinar will undoubtedly contribute to my professional growth. #Webinar #ProfessionalDevelopment #NeuropathicPain #AnimalModels #SPSR

Hello connections, Happy to share #Certificateofparticipation for attending 45th SPSR international webinar on ‘Preclinical Animal Models Studying Neurological Diseases’ organized by Society of Pharmaceutical Sciences and Research (SPSR) on March 24,2024. #SPSR #PharmaceuticalSciences #IJPSR #neurologicaldiseases #preclinical #animalstudy

Laekna Therapeutics receives the US FDA approval for P-III LAE002(Afuresertib) + LAE001 for Clinical trial protocol to treat mCRP #laekna #lae002 #lae001 #afuresertib #clinicaltrials #phase3 #phase2 #prostratecancer #mcrp

Marinomed Biotech AG announces results for the first quarter of 2024 · Revenues for the first quarter 2024 declined to pre-pandemic levels of EUR 0.7 million driven by high customer stock levels and return of seasonality · Q1 2024: New partnerships for Carragelose and Solv4U, agreement with financing partners for deferral of repayments and progress with P&G for the U.S. · Several initiatives for both Marinosolv and Carragelose assets to generate sufficient cash flows covering the Company’s financing needs “In the first quarter of 2024, we reported good progress for our Carragelose business: Two new distribution partnerships, positive clinical data for blocking allergens as well as the start of a clinical study for our moisturizing eye drops. After the reporting period, we saw the launch in Mexico as well as the first launch for the new allergy blocker in Austria. Regarding our partnership with Procter & Gamble, we are waiting for feedback from the FDA that would allow the launch of our product in the upcoming season”, Andreas Grassauer, CEO of Marinomed, mentions. “Furthermore, we concluded the second long-term partnership for Solv4U with Aché. After solving stability issues for our product candidates Budesolv and Tacrosolv, we are now also making good progress with our Marinosolv products in negotiations with potential partners and the conclusion of partnerships is closer than ever.” 📰 The full press release is available here: https://lnkd.in/dcPsgaTd 📈 The financial report is available here: https://lnkd.in/dbDwyePA #q1results #quaterlyresults #investorrelations #oceanofideas #Carragelose #Marinosolv #Solv4U #partnerships #Budesolv #Tacrosolv

Great sessions coming up this Sunday (Oct 22nd) to Tuesday (Oct 24th). Focus is on #RWE #patients and #optimization of #clinical #outcomes and #access #metrics. The theme of this year's conference: “Reimagining our Canadian Potential: Working Together through Partnerships and Collaborations” A variety of panel discussions with broad cognitive diversity on topics that matter to all Canadians - #equity and #timeliness in #access to #care #shaping the #future

Celebrating #Ozempic? Few know it almost didn’t make it to patients. At Loon Bio, we help you discover new indications. #Semaglutide, the active substance in Ozempic, was first developed and tested for Diabetes. We need more discoveries like this -- not left to chance — but systemized and purpose-driven patient-led Clinical Discovery. There are many drugs out there with potentially undiscovered secondary indications collecting dust, much like Semaglutide did until 2016. And there are many drugs or assets that were shelved or retired after failing Phase I clinical trials. They might have life-saving undiscovered indications, but no one is looking into them because no one has the time or capacity to sift through tons of data points. Here, we do just that: harness computing power to strategically sift through mountains of data to find insights and clues of potentially new indications.

Third year on the market, third year of constantly growing our portfolio of parameters. BioVendor Group CLIA solution helps with diagnostics not only in the Czech Republic, but also abroad. More than 50 developed parameters available and a large number of satisfied customers only confirm that the CLIA solution is going in the right direction. What other kits can we expect in the near future? And what is the opinion of our customers about the CLIA solution? Find out the answers in this brand new article https://bit.ly/49VHgJw! Do you have any questions? Email us at clia@biovendor.group or contact our colleague Zuzana Nekorancová. #BioVendorGroup #innovation #diagnostickits #biotechnology #diagnostics #laboratory

INDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio. The acquisition expands Lilly's portfolio to include Versanis' lead asset, bimagrumab, which is currently being assessed in a Phase 2b study alone and in combination with semaglutide in adults living with overweight or obesity. "Combining our current incretin portfolio, including tirzepatide, with activin receptor... https://phrmwb.com/3KFVnZk INDIANAPOLIS, Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Versanis Bio. The acquisition expands Lilly's portfolio to include Versanis' lead asset, bimagrumab, which is currently being assessed in a Phase 2b study alone and in combination with semaglutide in adults living with overweight or obesity. "Combining our current incretin portfolio, including tirzepatide, with activin receptor... #pharma #biotech #lifesciences #clinicalresearch #news #pharmiweb

Using animals to gain insights into human conditions is an age-old practice. It provides powerful insights into human biology but a mouse is not a human and nine out of ten drugs that enter clinical trials following animal testing fail in clinic because they are ultimately unsafe or ineffective in people. In this La Jolla Light article, Dr. David Brenner the president and Chief Executive of the Sanford Burnham Prebys Medical Research Institute, who specialises in liver disease, talks about the evolving landscape of pharmaceutical research and the use of New Alternative Methods (NAMs), like Organ-on-a-chip (OOC), to better support the drug development; to generate human-relevant data that expedite new therapeutics to clinic. Read the full article here: https://bit.ly/47VoJM5 #OrganOnAChip #OOC #NAM #MPS